These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 19269165)

  • 1. Intermittent hormone therapy and its place in the contemporary endocrine treatment of prostate cancer.
    Shaw G; Oliver RT
    Surg Oncol; 2009 Sep; 18(3):275-82. PubMed ID: 19269165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
    Soga N; Arima K; Sugimura Y
    Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
    Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
    Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiotherapy combined with hormonal therapy (RT-HT) in prostate cancer patients with low, intermediate, and high risk of biochemical recurrence: perspective and therapeutic gain analysis.
    Milecki P; Kwias Z; Martenka DJ
    Neoplasma; 2007; 54(1):7-15. PubMed ID: 17203887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [First line therapy in the treatment of metastatic prostate cancer].
    Sakai H; Kanetake H
    Gan To Kagaku Ryoho; 2003 Jan; 30(1):43-9. PubMed ID: 12557704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hormone therapy of locally advanced and metastatic prostate carcinoma].
    Rübben H
    Praxis (Bern 1994); 2001 Sep; 90(38):1641-4. PubMed ID: 11675917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.
    Moreau JP; Delavault P; Blumberg J
    Clin Ther; 2006 Oct; 28(10):1485-508. PubMed ID: 17157109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intermittent Complete Androgen Blockade in Metastatic Prostate Cancer.
    Rambeaud J
    Eur Urol; 1998 Dec; 35 Suppl S1():32-36. PubMed ID: 9858850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up.
    Bañez LL; Blake GW; McLeod DG; Crawford ED; Moul JW
    BJU Int; 2009 Aug; 104(3):310-4. PubMed ID: 19239458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The continued debate: intermittent vs. continuous hormonal ablation for metastatic prostate cancer.
    Gleave M; Klotz L; Taneja SS
    Urol Oncol; 2009; 27(1):81-6. PubMed ID: 19111804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of tamoxifen in hormone-resistant metastatic prostate cancer: possible relation with prolactin secretion.
    Lissoni P; Vigano P; Vaghi M; Frontini L; Giuberti C; Manganini V; Casu M; Brivio F; Niespolo R; Strada G
    Anticancer Res; 2005; 25(5):3597-9. PubMed ID: 16101186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
    Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
    BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Experience with Intermittent Androgen Suppression in Prostate Cancer: Minimum of 3 Years' Follow-Up.
    Goldenberg SL; Gleave ME; Taylor D; Bruchovsky N
    Mol Urol; 1999; 3(3):287-292. PubMed ID: 10851335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Usefulness and positioning of MAB therapy for prostate cancer].
    Akaza H; Chodak GW; Hirao Y
    Gan To Kagaku Ryoho; 2005 Oct; 32(10):1507-20. PubMed ID: 16227758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
    DiBlasio CJ; Malcolm JB; Hammett J; Wan JY; Aleman MA; Patterson AL; Wake RW; Derweesh IH
    BJU Int; 2009 Nov; 104(9):1208-14. PubMed ID: 19388987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [LHRH analogues for the treatment of prostate cancer: an evidence level-based analysis].
    Pfitzenmaier J; Altwein JE
    Aktuelle Urol; 2009 Mar; 40(2):100-8. PubMed ID: 19253209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by the South European Uroncological Group.
    Calais da Silva F; Calais da Silva FM; Gonçalves F; Santos A; Kliment J; Whelan P; Oliver T; Antoniou N; Pastidis S; Marques Queimadelos A; Robertson C
    Eur Urol; 2014 Aug; 66(2):232-9. PubMed ID: 23582949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The current status of intermittent androgen deprivation (IAD) therapy for prostate cancer: putting IAD under the spotlight.
    Tunn U
    BJU Int; 2007 Jan; 99 Suppl 1():19-22; discussion 23-4. PubMed ID: 17229164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5alpha-reductase.
    Vis AN; Schröder FH
    BJU Int; 2009 Nov; 104(9):1191-7. PubMed ID: 19624596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.